Quick answers
- What is Nabumetone used for?
- The FDA-approved label (Relafen Ds, Carwin Pharmaceutical Associates, LLC, January 8, 2024) says: “Carefully consider the potential benefits and risks of nabumetone tablets and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals […]. Nabumetone tablets are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Nabumetone have a boxed warning?
- Yes. The FDA label for Relafen Ds has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Nabumetone?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Nabumetone been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Nabumetone?
- 26 companies list prescription products of Nabumetone in the FDA NDC Directory, including Bryant Ranch Prepack, Proficient Rx LP and PD-Rx Pharmaceuticals, Inc..
What Nabumetone is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Carefully consider the potential benefits and risks of nabumetone tablets and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals […]. Nabumetone tablets are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis
— FDA label: Relafen Ds, Carwin Pharmaceutical Associates, LLC, effective January 8, 2024. Read the full label on DailyMed →
The FDA has 48 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
48 of 48 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet · Tablet, film coated |
|---|---|
| Route | Oral |
| Prescription products | 64 in the FDA NDC Directory |
| Brand names | Relafen Ds |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| nabumetone 1000 mg tablet | Brand: Relafen Ds | $31.67 per tablet |
| nabumetone 500 mg tablet | Generic | $0.1345 per tablet |
| nabumetone 500 mg tablet, film coated | Generic | $0.1345 per tablet |
| nabumetone 750 mg tablet | Generic | $0.1753 per tablet |
| nabumetone 750 mg tablet, film coated | Generic | $0.1753 per tablet |
NADAC list of November 4, 2026; these prices took effect between June 17, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack12 products
- Proficient Rx LP5 products
- PD-Rx Pharmaceuticals, Inc.3 products
- LGM Pharma Solutions, LLC3 products
- Northwind Health Company, LLC3 products
- Direct_Rx2 products
- St. Mary's Medical Park Pharmacy2 products
- Lupin Pharmaceuticals, Inc.2 products
- Preferred Pharmaceuticals Inc.2 products
- Cipla USA Inc.2 products
- ANI Pharmaceuticals, Inc.2 products
- A-S Medication Solutions2 products
- Exelan Pharmaceuticals Inc.2 products
- Actavis Pharma, Inc.2 products
- Sportpharm LLC2 products
- Remedyrepack Inc.2 products
- Asclemed USA, Inc.2 products
- ScieGen Pharmaceuticals, Inc.2 products
- Quality Care Products, LLC2 products
- Advanced Rx of Tennessee, LLC2 products
- Westminster Pharmaceuticals, LLC2 products
- Chartwell RX, LLC2 products
- Redpharm Drug1 product
- Advanced Rx Pharmacy of Tennessee, LLC1 product
- Carwin Pharmaceutical Associates, LLC1 product
- American Health Packaging1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (7)
- ANDA075280Chartwell Rx · February 25, 2002
- ANDA078671Invagen Pharms · March 7, 2008
- ANDA078420Sciegen Pharms · September 24, 2008
- ANDA090445Annora Pharma · January 12, 2011
- ANDA091083Watson Labs · June 13, 2011
- ANDA203166Lgm Pharma · August 30, 2019
- ANDA219118Novitium Pharma · January 7, 2025
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 311892, 311893, 427726, 2200291 |
|---|---|
| SPL set ID of the quoted label | a9a0af85-6c43-4a2d-ba75-0be4ca64c931 |
| FDA labels (SPL) | 48 |
| FDA applications | 7 ANDA |
| Active ingredients (FDA) | NABUMETONE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Relafen Ds, Carwin Pharmaceutical Associates, LLC, effective January 8, 2024; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →